A Study of Atezolizumab in Advanced Solid Tumors

PHASE2CompletedINTERVENTIONAL
Enrollment

474

Participants

Timeline

Start Date

July 16, 2015

Primary Completion Date

April 4, 2018

Study Completion Date

July 28, 2020

Conditions
Tumors
Interventions
DRUG

Atezolizumab (MPDL3280A), an engineered anti-programmed death-ligand 1 (PD-L1) antibody

Atezolizumab will be given as IV infusion over 60 minutes on Day 1 of Cycle 1, then over 30 minutes (as tolerated) on Day 1 of each subsequent 3-week cycle.

Trial Locations (48)

4

St Vincent'S Uni Hospital; Medical Oncology, Dublin

1090

Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Chemotherapie & Infektionskrankhei, Vienna

1708

Freiburger Spital; Onkologie, Fribourg

2730

Herlev Hospital; Afdeling for Kræftbehandling, Herlev

5000

Odense Universitetshospital, Onkologisk Afdeling, Klinisk Forsknings Enhed, Odense C

5021

Haukeland Universitetssjukehus; Klinisk forskningspost, Bergen

8036

LKH-UNIV. KLINIKUM GRAZ; Klinische Abteilung für Onkologie, Graz

8200

Aarhus Universitetshospital; Kræftafdelingen, Aarhus N

9007

Kantonsspital St. Gallen; Onkologie/Hämatologie, Sankt Gallen

10027

Columbia University Medical Center, New York

10065

Memorial Sloan Kettering, New York

20133

Fondazione IRCCS Istituto Nazionale dei Tumori, Milan

20246

Uniklinik-Eppendorf; Zentren F. Innere Medizin-Klinik U. Poliklinik, Hamburg

22030

Trakya University Medical Faculty, Edirne

31008

Clinica Universitaria de Navarra; Servicio de Oncologia, Pamplona

33076

Institut Bergonie, Bordeaux

34300

Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul

34384

Prof. Dr. Cemil Tascioglu City Hospital; Med Onc, Istanbul

37203

Sarah Cannon Cancer Center and Research Institute, Nashville

44195

The Cleveland Clinic Foundation, Cleveland

53100

Azienda Ospedaliera Universitaria Senese, U.O.C. Immunoterapia Oncologica, Siena

54290

Klinikum Mutterhaus der Borromaeerinnen gGmbH; Haematologie/Onkologie, Trier

69120

Universitatsklinik Heidelberg; Universitätshautklinik und Nationales Centrum für Tumorerkrankungen, Heidelberg

69373

Centre Leon Berard; Departement Oncologie Medicale, Lyon

75475

Hopital Saint Louis, Service D Oncologie Medicale, Paris

77030

MD Anderson Cancer Center, Houston

80131

Istituto Nazionale Tumori Fondazione G. Pascale, Napoli

94805

Institut Gustave Roussy, Villejuif

115478

Russian Oncology Research Center n.a. N.N. Blokhin Dpt of Clinical Pharmacology and Chemotherapy, Moscow

197758

S-Pb clinical scientific practical center of specialized kinds of medical care (oncological), Saint Petersburg

20231-050

INCA 1- Instituto Nacional de Câncer X, Rio de Janeiro

90035-903

Hospital das Clinicas - UFRGS, Porto Alegre

01246-000

Instituto do Cancer do Estado de Sao Paulo - ICESP, São Paulo

V5Z 4E6

BCCA-Vancouver Cancer Centre, Vancouver

M5G 2M9

University Health Network; Princess Margaret Hospital; Medical Oncology Dept, Toronto

00029

Helsinki University Central Hospital; Dept of Oncology, Helsinki

Unknown

St James' Hospital; Cancer Clinical Trials Office, Dublin

1066 CX

Antoni van Leeuwenhoek Ziekenhuis, Amsterdam

3015 GD

Erasmus MC, Rotterdam

3584 CX

Universitair Medisch Centrum Utrecht, Utrecht

0310

Oslo Universitetssykehus HF; Radiumhospitalet, Oslo

85-796

Centrum Onkologii w Bydgoszczy, Bydgoszcz

80-214

Uniwersyteckie Centrum Kliniczne; Klinika Onkologii i Radioterapii, Gdansk

02-781

Narodowy Instytut Onkologii im. M.Sklodowskiej-Curie; Klinika Now. Tkanek Miekkich,Kosci i Czer., Warsaw

08035

Hospital Univ Vall d'Hebron; Servicio de Oncologia, Barcelona

06230

Hacettepe Uni Medical Faculty Hospital; Oncology Dept, Sihhiye/Ankara

CH63 4JY

Clatterbridge Cancer Centre, Bebington

SO16 6YD

Southampton General Hospital; Medical Oncology, Southampton

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02458638 - A Study of Atezolizumab in Advanced Solid Tumors | Biotech Hunter | Biotech Hunter